bioAffinity Technologies, Inc. (BIAF) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $10.14 (+15.89%), Market cap $0.01B, 52-week low–high $0.17 ~ $5.29.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests un
Financial statements, price targets, institutional (13F) holdings and related news for bioAffinity Technologies, Inc. are updated in real time on BlackAll Trade.
bioAffinity Technologies, Inc. trades at $10.14 (+15.89%). Real-time quotes and charts are available on BlackAll Trade.
bioAffinity Technologies, Inc. has a market cap of about $0.01B.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analys